Insider Selling: Aradigm Co. (ARDM) Insider Sells 17,011 Shares of Stock

Aradigm Co. (NASDAQ:ARDM) insider Juergen Kurt Froehlich sold 17,011 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $1.53, for a total value of $26,026.83. Following the transaction, the insider now owns 90,853 shares in the company, valued at approximately $139,005.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Aradigm Co. (NASDAQ ARDM) traded down $0.12 on Wednesday, reaching $1.38. The company’s stock had a trading volume of 316,741 shares, compared to its average volume of 887,361. The company has a debt-to-equity ratio of -1.59, a quick ratio of 1.65 and a current ratio of 1.65. Aradigm Co. has a 12-month low of $0.78 and a 12-month high of $7.35. The company has a market capitalization of $22.72, a PE ratio of -1.41 and a beta of 1.56.

Aradigm (NASDAQ:ARDM) last issued its earnings results on Thursday, November 2nd. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.05. The company had revenue of $2.73 million for the quarter. equities analysts expect that Aradigm Co. will post -0.8 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Aradigm stock. Jane Street Group LLC acquired a new stake in shares of Aradigm Co. (NASDAQ:ARDM) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 29,025 shares of the company’s stock, valued at approximately $122,000. Jane Street Group LLC owned approximately 0.19% of Aradigm at the end of the most recent reporting period. 32.02% of the stock is currently owned by institutional investors.

A number of equities analysts have issued reports on ARDM shares. Zacks Investment Research cut Aradigm from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th. ValuEngine upgraded Aradigm from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, Ladenburg Thalmann Financial Services cut Aradigm from a “buy” rating to a “neutral” rating in a report on Friday, January 12th.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at

Aradigm Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with's FREE daily email newsletter.

Leave a Reply